Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Mallinckrodt
Harvard Business School
Baxter
McKesson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ISRADIPINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Isradipine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00593463 ↗ Drug Discrimination in Methadone-Maintained Humans Study 1 Completed University of Arkansas Phase 1 2006-09-01 This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
NCT00753636 ↗ Parkinson's Disease Isradipine Safety Study Completed Northwestern Memorial Hospital Phase 2 2008-04-01 The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice. Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent. Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading.
NCT00753636 ↗ Parkinson's Disease Isradipine Safety Study Completed Northwestern University Phase 2 2008-04-01 The objective of this study is to establish the safety and tolerability of isradipine, sustained release preparation in patients with PD. This study is a logical continuation of the project that is being completed now and is conducted in preparation to NIH submission of the pivotal study on the efficacy of this agent for neuroprotection in PD. This study is conducted in parallel with Dr. Surmeier's work on further development of the preclinical data. The focus of his work now is to establishing the correlation between the dose that demonstrated neuroprotective effect in animal model and the dose used for clinical practice. Hypothesis 1: Patients with PD will be able to tolerate isradipine across the FDA recommended dose range. We expect 10% attrition due to hypotensive effect of the agent. Hypothesis 2: Patients with PD and concomitant stable hypertension will be able to tolerate isradipine provided that the dose of the concomitant antihypertensive agent is adjusted based on the blood pressure reading.
NCT00909545 ↗ Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Completed Michael J. Fox Foundation for Parkinson's Research Phase 2 2009-07-01 The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
NCT00909545 ↗ Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Completed Northwestern University Dixon Fund Phase 2 2009-07-01 The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
NCT00909545 ↗ Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Completed The Parkinson Study Group Phase 2 2009-07-01 The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Isradipine

Condition Name

Condition Name for Isradipine
Intervention Trials
Parkinson Disease 2
Opioid Dependence 1
Parkinson's Disease 1
Schizoaffective Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Isradipine
Intervention Trials
Parkinson Disease 3
Hypertension 2
Psychotic Disorders 1
Tobacco Use Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Isradipine

Trials by Country

Trials by Country for Isradipine
Location Trials
United States 52
Canada 4
Hungary 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Isradipine
Location Trials
New York 4
Massachusetts 3
Illinois 3
Pennsylvania 3
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Isradipine

Clinical Trial Phase

Clinical Trial Phase for Isradipine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Isradipine
Clinical Trial Phase Trials
Completed 7
Recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Isradipine

Sponsor Name

Sponsor Name for Isradipine
Sponsor Trials
The Parkinson Study Group 2
University of Arkansas 2
National Institute on Drug Abuse (NIDA) 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Isradipine
Sponsor Trials
Other 19
NIH 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Mallinckrodt
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.